{"product_id":"global-diabetes-care-devices-market","title":"Global Diabetes Care Devices Market 2026","description":"\u003ch2\u003eMarket at a Glance\u003c\/h2\u003e\n\u003cp\u003eThe global diabetes care devices market is forecast to reach \u003cstrong\u003eUSD 40.69 billion by 2031\u003c\/strong\u003e, up from an estimated USD 25.1 billion in 2025, representing an \u003cstrong\u003e8.4% CAGR\u003c\/strong\u003e. Continuous glucose monitoring and insulin pumps are reshaping revenue around recurring consumables, automated delivery and connected treatment.\u003c\/p\u003e\n\u003ch2\u003eInsulin pumps grow fastest; CGM delivers the largest revenue gain\u003c\/h2\u003e\n\u003cp\u003eInsulin pumps and infusion consumables are forecast to grow at \u003cstrong\u003e11.5% annually from 2025 to 2031\u003c\/strong\u003e, supported by automated insulin delivery and conversion from injections. CGM expands at 9.8% and contributes the largest absolute increase in revenue. Together, these two businesses are projected to account for \u003cstrong\u003e87.8% of market revenue in 2031\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eTraditional fingerstick monitoring retains a role in affordable and supplementary testing, but migration among frequent testers puts pressure on test-strip revenue. Connected insulin pens provide another route to integrating dose records with glucose data. These different adoption paths make reimbursement, compatibility and sustained use central to commercial performance.\u003c\/p\u003e\n\u003ch2\u003eRecurring use changes the competitive equation\u003c\/h2\u003e\n\u003cp\u003eSensor replenishment, disposable pods and infusion supplies extend revenue beyond the initial device purchase. Established suppliers benefit from distribution reach and reimbursement access, while new platforms compete on wearability, ease of use and system compatibility. Patient retention and reliable supply influence how adoption translates into repeat revenue.\u003c\/p\u003e\n\u003cp\u003eNorth America is expected to remain the largest regional market. Asia Pacific is forecast to grow faster, as access expands across markets with different reimbursement arrangements and affordability constraints. The report connects these regional differences with product adoption, payment pathways and manufacturer strategies.\u003c\/p\u003e\n\u003ch2\u003eWhat the report covers\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAnnual market sizing:\u003c\/strong\u003e Global revenue estimates for 2025 and annual forecasts for 2026–2031, with four product categories, market totals and category growth rates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct markets:\u003c\/strong\u003e CGM devices and consumables; SMBG meters, strips and associated lancing accessories; insulin pumps and infusion consumables; insulin pen hardware and smart accessories.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegional analysis:\u003c\/strong\u003e North America, Europe, Asia Pacific and other regions, including 2025 and 2031 revenue, shares and growth rates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTechnology and adoption:\u003c\/strong\u003e Automated insulin delivery, patch and durable pumps, implantable monitoring, multi-analyte sensing, connected injection management and the development status of alternative approaches.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetition and commercial models:\u003c\/strong\u003e Supplier strategies, system partnerships, reimbursement, recurring consumables, manufacturing and user retention.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTreatment dynamics:\u003c\/strong\u003e Type 1 and type 2 diabetes pathways, digital care integration and the implications of GLP-1 medicines for device use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eMarket revenue measures manufacturer-level device value. Insulin pen figures cover hardware and smart accessories, including the estimated hardware component of prefilled pens, rather than the insulin they contain.\u003c\/p\u003e\n\u003ch2\u003eParticipants examined\u003c\/h2\u003e\n\u003cp\u003eCoverage includes Abbott, Dexcom, Insulet, MiniMed, Tandem, Beta Bionics, Senseonics, Roche, Ascensia\/PHC, LifeScan, Sinocare, mylife Diabetes Care, Ypsomed, Sequel Med Tech, Diabeloop, Tidepool, Novo Nordisk, Sanofi and Eli Lilly.\u003c\/p\u003e\n\u003ch2\u003eReport contents\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eMarket Overview\u003c\/li\u003e\n\u003cli\u003eGlobal Market Size and Growth\u003c\/li\u003e\n\u003cli\u003eProduct Markets\u003c\/li\u003e\n\u003cli\u003eCompetitive Landscape and Company Strategies\u003c\/li\u003e\n\u003cli\u003eDemand, Reimbursement and Business Models\u003c\/li\u003e\n\u003cli\u003eRegional Markets\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eDelivery details\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eFormat:\u003c\/strong\u003e English PDF\u003cbr\u003e\u003cstrong\u003eLength:\u003c\/strong\u003e 16 pages\u003cbr\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e October 2026\u003cbr\u003e\u003cstrong\u003eIncluded:\u003c\/strong\u003e Six tables, three data visualizations and 32 references\u003cbr\u003e\u003cstrong\u003eDelivery:\u003c\/strong\u003e Automatic digital download after payment\u003c\/p\u003e","brand":"Tanalyze","offers":[{"title":"Default Title","offer_id":50130549244059,"sku":null,"price":175.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0729\/4130\/6011\/files\/global-diabetes-care-devices-cover.jpg?v=1794304532","url":"https:\/\/strategyhelix.com\/products\/global-diabetes-care-devices-market","provider":"StrategyHelix","version":"1.0","type":"link"}